ストックスクリーナーアプリを入手
0.721
1.11%
0.0079
前日終値:
$0.7131
開ける：
$0.7
24時間の取引高:
437.46K
Relative Volume:
1.17
時価総額：
$13.97M
収益：
$1.16M
当期純損益:
$-12.02M
株価収益率:
-0.6945
EPS:
-1.0381
ネットキャッシュフロー:
$-10.16M
1週間 パフォーマンス:
-1.90%
1か月 パフォーマンス:
-46.19%
6か月 パフォーマンス:
-53.78%
1年 パフォーマンス:
-66.15%
1日の値動き範囲:
$0.70
$0.7573
1週間の範囲:
$0.69
$0.82
52週間の値動き範囲:
$0.69
$3.78
Dare Bioscience Inc Stock (DARE) Company Profile
Compare DARE vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
0.721 | 15.68M | 1.16M | -12.02M | -10.16M | -1.0381 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dare Bioscience Inc (DARE) 最新ニュース
Drugmakers still struggling to keep up with spiking estrogen patch demand - AOL.com
Daré Bioscience (DARE) Q2 2026 Earnings Call Transcript - AOL.com
Dare Bioscience (NASDAQ: DARE) sets up $12.4M in potential warrant cash - Stock Titan
DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List - sahmcapital.com
Forbes puts a women's health biotech CEO on its 2026 innovation list - Stock Titan
DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 "50 Over 50: Innovation" List - Nasdaq
Dare Bioscience Inc (DARE) (Q2 2026) Earnings Call Highlights: C - GuruFocus
Dare Bioscience Prices $6.0 Million Registered Direct Offering - Minichart
Form 8K Dare Bioscience Inc For: 17 August By Investing.com - Investing.com Nigeria
Daré Bioscience Raises ~$6 Million in Equity Offering at $1.37 With Attached Warrants - TradingView
H.C. Wainwright reiterates Dare Bioscience stock rating at buy By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Q2 2026 Dare Bioscience Inc Earnings Call Transcript - GuruFocus
H.C. Wainwright Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Daré Bioscience raises $6M in registered direct offering By Investing.com - Investing.com India
Dare Bioscience Prices $6 Million Registered Direct Offering; Shares Fall - marketscreener.com
Daré Bioscience raises $6M in registered direct offering - Investing.com
Daré Bioscience Announces $6.0 Million Registered Direct Offering and Concurrent Private Placement - moomoo.com
Daré Bioscience Announces Pricing of $6.0 Million - GlobeNewswire
Daré Bioscience, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Dare Bioscience earnings beat by $0.11, revenue topped estimates - Investing.com Canada
Daré Bioscience (DARE) Launches New Product Amid Challenging Val - GuruFocus
Dare Bioscience (DARE) Q2 Results Highlight Challenges Amid Low Valuation on Price-to-Sales Basis - GuruFocus
Earnings call transcript: Daré Bioscience Q2 2026 loss narrows as stock jumps after hours - Investing.com
Dare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Dare Bioscience Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Dare Bioscience Q2 net loss narrows as revenue rises, R&D expenses decline - TradingView
Dare Bioscience Q2 Results: Net loss narrows to $3.0M, cash falls - scanx.trade
Dare Bioscience, Inc. 2026: Revenue $187.55K, EPS ($0.2) — 10-Q Summary - TradingView
Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances - The Manila Times
Daré Bioscience launches Flora Sync, its first directly commercialized product - Stock Titan
Dare Bioscience reports Q2 2026: $0.19M revenue, $2.98M net loss, cash $12.6M - TradingView
Dare Bioscience Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Transcript : Daré Bioscience, Inc.Special Call - marketscreener.com
Women keep recommending £20 gynaecologist-backed dryness buy that sold out 5 times - AOL.co.uk
Dare Bioscience Inc (DARE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dare Bioscience (DARE.US) will release its earnings report after market close on August 13. - Moomoo
Dare Bioscience (DARE) Eases 0.75% to $1.33: Stock Hovers Between Key Support and ResistanceHedge Fund Exposure - dars.gov.et
Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026 - The Manila Times
Daré Bioscience to Host Second Quarter 2026 Financial - globenewswire.com
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Darling: Q2 Earnings Snapshot - AOL.com
Dare Bioscience Expands Access Options for DARE to PLAY and Specialized Menopause Care through Strategic Collaboration with MyMenopauseRx - marketscreener.com
Dare Bioscience Inc (DARE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dare Slides on MyMenopauseRx Hookup - Baystreet.ca
Daré Bioscience partners with menopause telehealth platform By Investing.com - Investing.com Nigeria
Daré Bioscience partners with menopause telehealth platform - Investing.com
Daré Bioscience Expands Access Options for DARE to PLAY™ - globenewswire.com
Women Exploring DARE to PLAY Can Now Reach Menopause Specialists - Stock Titan
DARE|Dare Bioscience Inc|Price:1.330|Chg%:+0.050 - TradingKey
Dare Bioscience Inc (DARE) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):